______________________________________________________________________________________________ Adragos Pharma
batches, and commercial lines elsewhere running at volume. For biotech clients who need one partner from early clinical supply through to launch, that range matters considerably.
Adragos’ approach to suppliers follows the same logic. The company uses the market analytics platform QYOBO for pharmaceutical ingredients and chemicals to gain visibility of its supplier base and reduce reliance on a single sourcing market. It can also show which sites and products would be affected by certain events, such as earthquakes. The approach reflects wider industry thinking, as Supply Chain Wizard is working on a digitalization project with Adragos, and the consultancy firm argues that, in 2026, agility is becoming a requirement in compliance, resilience, and patient-access for pharma manufacturers.
As pharma and biotech sponsors increasingly hand sterile manufacturing to specialists rather than build their own lines, Adragos is betting on continued outsourcing – and the company’ s strategy leans on that trend. It also targets rare diseases and biologics and is building its US presence through partnerships and network expansion. Though a capacity-led strategy carries the risk of lines built ahead of demand, and consequently sitting unused, Adragos’ ambition is untouchable as it takes on the task of filling them.
Looking ahead, the company’ s next moves are already visible – its Japanese tablet expansion is planned, and it continues to pursue acquisitions. Each new site adds capacity and one more integration project. The measure of the strategy over the next two years will be how quickly its acquired capacity – from Switzerland to Norway – starts carrying customer volume under a single quality system. ■
adragos-pharma. com
manufacturing-today. com 277